Results 21 to 30 of about 4,504 (155)

The Outcome of Antifungal Prophylaxis with Posaconazole in Patients with Acute Myeloid Leukemia: A Single-Center Study

Turkish Journal of Hematology, 2018
Objective: Invasive fungal infections (IFIs) are a significant cause of morbidity and mortality among neutropenic patients undergoing chemotherapy for acute myeloid leukemia (AML) and stem cell transplantation.
Vildan Özkocaman, Fahir Özkalemkaş, Serdar Seyhan, Beyza Ener, Ahmet Ursavaş, Tuba Ersal, Esra Kazak, Ezgi Demirdöğen, Reşit Mıstık, Halis Akalın   +9 more
doaj   +1 more source

Voriconazole and posaconazole therapeutic drug monitoring: a retrospective study

Annals of Clinical Microbiology and Antimicrobials, 2017
Background Therapeutic drug monitoring (TDM) aims to minimize the clinical impact of posaconazole and voriconazole pharmacokinetic variability. However, its benefits on clinical outcomes are still being defined.
Whitley M. Yi, Kelly E. Schoeppler, Jaclyn Jaeger, Scott W. Mueller, Robert MacLaren, Douglas N. Fish, Tyree H. Kiser   +6 more
doaj   +1 more source

Evaluation of antifungal susceptibility and clinical characteristics in fungal keratitis in a tertiary care center in North India

Indian Journal of Ophthalmology, 2022
Purpose: To study the antifungal susceptibility of common corneal pathogenic fungi to antifungal agents in the North Indian population. Methods: Prospective study of the antifungal sensitivity testing (natamycin, amphotericin B, voriconazole ...
Murugesan Vanathi, Ravinder Naik, Navneet Sidhu, Nishat Hussain Ahmed, Noopur Gupta, Radhika Tandon   +5 more
doaj   +1 more source

Pharmacokinetics and Pharmacodynamics of Posaconazole [PDF]

, 2020
Contains fulltext : 220128.pdf (Publisher’s version ) (Open Access)Posaconazole is typically used for preventing invasive yeast and mold infections such as invasive aspergillosis in high-risk immunocompromised patients.
Krekels, E.H.J., Chen, L., Buil, J.B., Knibbe, C.A.J., Bruggemann, R.J.M., Verweij, P.E.   +5 more
core   +2 more sources

Comparison of clinical pharmacology of voriconazole and posaconazole [PDF]

, 2016
Despite greater knowledge and possibilities in pharmacotherapy, fungal infections remain a challenge for clinicians. As the population of immunocompromised patients and those treated for their hematologic ailments increases, the number of fungal ...
Anna Wiela-Hojeńska, Beata M Sienkiewicz, Beata M. Sienkiewicz, Łukasz Łapiński   +3 more
core   +1 more source

Effects of Posaconazole on Tacrolimus Population Pharmacokinetics and Initial Dose in Children With Crohn’s Disease Undergoing Hematopoietic Stem Cell Transplantation

Frontiers in Pharmacology, 2022
The present study explored the effects of posaconazole on tacrolimus population pharmacokinetics (PPK) in children with Crohn’s disease (CD) undergoing hematopoietic stem cell transplantation (HSCT).
Xiao Chen, Dongdong Wang, Feng Zheng, Lin Zhu, Yidie Huang, Yiqing Zhu, Ying Huang, Hong Xu, Zhiping Li   +8 more
doaj   +1 more source

Utility of posaconazole therapeutic drug monitoring and assessment of plasma concentration threshold for effective prophylaxis of invasive fungal infections: a meta-analysis with trial sequential analysis

BMC Infectious Diseases, 2018
Background Posaconazole therapeutic drug monitoring (TDM) is increasingly used in clinical practice. However, the utility of posaconazole TDM and the target of posaconazole plasma concentration for clinical successful prophylaxis remain uncertain and ...
Lu Chen, Yan Wang, Tao Zhang, Ying Li, Ti Meng, Leichao Liu, Ruifang Hao, Yalin Dong   +7 more
doaj   +1 more source

Rhabdomyolysis Following Initiation of Posaconazole Use for Antifungal Prophylaxis in a Patient With Relapsed Acute Myeloid Leukemia

Journal of Investigative Medicine High Impact Case Reports, 2017
Posaconazole is a commonly used medication for antifungal prophylaxis in patients with high-risk acute leukemia, such as acute myeloid leukemia. Despite clinical data that show that posaconazole is superior to other antifungal prophylaxis medications ...
Mayur D. Mody MD, Deepak Ravindranathan MD, Harpaul S. Gill MD, Vamsi K. Kota MD   +3 more
doaj   +1 more source

Posaconazole prophylaxis during front-line chemotherapy of acute myeloid leukemia: a single-center, real-life experience

Haematologica, 2012
Background Posaconazole is effective as primary antifungal prophylaxis of invasive fungal diseases in patients with acute myeloid leukemia.Design and Methods The impact of primary antifungal prophylaxis administered during front-line chemotherapy for ...
Corrado Girmenia, Anna Maria Frustaci, Giuseppe Gentile, Clara Minotti, Claudio Cartoni, Saveria Capria, Silvia Maria Trisolini, Angela Matturro, Giuseppina Loglisci, Roberto Latagliata, Massimo Breccia, Giovanna Meloni, Giuliana Alimena, Robin Foà, Alessandra Micozzi   +14 more
doaj   +1 more source

Posaconazole salvage treatment in paediatric patients: a multicentre survey [PDF]

, 2010
While a paediatric dosage has not been defined, posaconazole is occasionally being used in children. We conducted a multicentre retrospective survey and identified 15 patients (median age 10 years [range 3.6-17.5]) who received posaconazole salvage ...
Lüer, S, Wagner, H. J., Lehrnbecher, T, Phillips, R, Attarbaschi, A., Wiesel, T, Groll, A. H., Scholz, J, Lehrnbecher, Thomas, Groll, A H, Wagner, Hans-Joachim, Phillips, R., Wiesel, Thomas, Garbino, J., Gruhn, Bernd, Kontny, Udo, Duerken, M, Attarbaschi, A, Lehrnbecher, T., Gruhn, B., Duerken, M., Wagner, H J, Gruhn, B, Attarbaschi, Andishe, Garbino, J, Kontny, U., Scholz, J., Kontny, U, Groll, Andreas H., Lüer, S., Dürken, Matthias, Wiesel, T.   +31 more
core   +2 more sources